In adults with type 2 diabetes, once-daily liraglutide was linked to a higher risk of non-adherence than once-weekly GLP-1 receptor agonists (risk ratio 0.89 for weekly versus daily dosing).
In plain wordsIn adults with type 2 diabetes, people on once-daily liraglutide were more likely to be non-adherent than people on once-weekly GLP-1 drugs.
- Peptide
- Liraglutide
- Outcome
- IncreaseNon-adherence (proportion of days covered below 80)
- Study
n = 75,159
- Comparator
- Once-weekly GLP-1 receptor agonists (dulaglutide, albiglutide, exenatide extended release)
- Analysis
- Primary
- Outcome group
- Treatment adherence and retention · Metabolic and weight
- Studied dose
- Dose not stated
Measurements
- RR
- 0.89 NA
- once weekly vs once daily
Source sentences
Upon meta-analysis, once weekly GLP-1RA dosing was associated with an 11% lower risk of non-adherence compared to once daily dosing (risk ratio = 0.89; 95% confidence interval = 0.83-0.95; I2 = 89%).
2 context sentences(design, population, supporting numbers)
A total of 7 studies evaluating 75 159 patients (range: 2886-30 097) with T2D were included.
Injectable GLP-1RAs dosed once weekly were either dulaglutide, albiglutide or exenatide extended release; while liraglutide was the injectable once daily agent evaluated in all included studies.